Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immune Globulin

Posted by Lindsay Haggerty on Nov 12, 2015

Touching a network across healthcare in pharma, payer and provider, MMIT's team of experts takes a closer look at immune globulin products in our most recent Reality Check. The following highlights some of our key takeaways from the piece.

Payer Coverage: A market access breakdown by route of administrations reveals a clearer landscape view of IG products. Subcatenous products have the highest percentage of lives processing exclusively through medical benefit.

Source: MMIT data as of Q4 2015

Trends: In order to advance the administration of IVIG products, Pharma Practice News suggests that health systems continue to experiment with new optimiztion methods. Providers focus on this optimization in order to lower the risks of side effects and incidents of adverse events. Additionally, Jerry Siegal of PharmaD highlights that new IG products improve availability to plasma-based treatments for HCPs.

Key Findings: Although IG products can address many patient conditions, the FDA only approves most for a minority of indications. Therefore, many provider and pharmacist communities establish a set of guidelines for ethical, off-label use. Payers also reimburse the IG class in a unique manner compared to other highly managed classes. Payers actually implement off-label utilization lists when sufficient scientific research supports their use. On another note, patients have more options than ever to seek alternative treatments. Although not many manufacturers currently offer plasma-based therapeutic areas, pipeline research suggests that additional manufacturers plan on entering the market.

In the full Reality Check on immune globulin products below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

 View Reality Check

Topics: Market Access